Navigation Links
QRxPharma Successfully Completes Phase 1 Studies for MoxDuo® CR
Date:4/10/2012

rement of opioid blood levels over time revealed a MoxDuo CR profile consistent with expectations for a once to twice-daily formulation.

The second study demonstrated that food consumption does not alter the pharmacokinetic profiles of morphine and oxycodone from MoxDuo CR (30 mg/20 mg) tablets using a two-way crossover design with 17 healthy volunteers. To demonstrate the effects of chronic use on steady-state blood levels, this study also measured the repetitive-dose pharmacokinetic profiles of morphine and its metabolites as well as oxycodone during repetitive (twice daily) administration of MoxDuo CR tablets for 5 days.

The MoxDuo CR tablets used in these clinical tests included QRxPharma's proprietary Abuse Deterrence Formulation (ADF) technology. As an indication of tamper resistance, attempts to extract morphine or oxycodone by crushing and solubilising in water or alcohol resulted in very limited (less than 15%) drug recovery. In addition, the ADF technology did not impair human bioavailability of the opioids following oral administration.

"Clinical performance of the oral MoxDuo CR formulation clearly exceeded our expectations. When directly compared to OxyContin, the largest selling opioid for chronic pain, MoxDuo CR demonstrated superior bioavailabilty and sustained blood levels for over 12 hours, especially in the 12-24 hour time period. At steady-state, MoxDuo CR provided very low fluctuations of oxycodone. MoxDuo CR appears to be a true once or twice a day delivery system for dual opioids," said Dr. Ed Rudnic, Chief Operating Officer, QRxPharma. "We expect that MoxDuo CR's sustained blood levels, ADF attributes and potential side effect benefits will enhance the tolerability and acceptability of MoxDuo CR in the global chronic pain marketplace."

The CR formulation of MoxDuo encompasses the same 3:2 ratio of morphine and oxycodone as in MoxDuo IR, QRxPharma's immediate release acute pain formulation that is scheduled for PDUF
'/>"/>

SOURCE QRxPharma
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. QRxPharma Doses First Patients in Phase III Clinical Trial Program for its Dual Opioid Pain Therapy
2. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
3. QRxPharma Releases Additional Phase 3 Data for Q8003IR Dual Opioid Pain Therapy
4. QRxPharma Successfully Completes Comparative Study for Dual-Opioid(TM) Pain Therapy
5. QRxPharma Inks Deal with Patheon for the Manufacture of MoxDuo(TM)CR
6. QRxPharma Limited Announces A$21.6 Million Fully Underwritten Capital Raising
7. QRxPharma Initiates Second Pivotal Phase 3 Study of MoxDuo(TM)IR Dual-Opioid(TM) for NDA Submission
8. QRxPharma Limited and China Aoxing Pharmaceutical Company Announce Strategic Alliance for Development of MoxDuo(R)IV
9. QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo(R)IR in Patients with Post-Surgical Pain
10. QRxPharma Successfully Completes Comparative Phase 1 Proof-of-Concept Study for MoxDuo(R) CR Tablet Formulation
11. QRxPharma Receives Positive Feedback from Scientific Advice Meetings in Europe on MoxDuo®IR Development and Registration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) today reported financial ... "During the quarter, we achieved a key ... securing a partner to accelerate the development and commercialization of ... we do not have a commercial presence while also retaining ... the value of PIXUVRI for CTI and help us achieve ...
(Date:10/30/2014)... -- Today Eli Lilly and Company (NYSE: ... program to increase the global supply of medicines for ... Lilly donating manufacturing technology and know-how for two antibiotics ... India , Russia ... all MDR-TB ,hot spots., It also served as the ...
(Date:10/27/2014)... NEW YORK , Oct. 27, 2014  In the last ... parts of Africa to a worldwide crisis ... down with the virus and died, and two nurses were infected. ... how this could happen, the use of modern technology, such as ... went largely unnoticed. This week, InformationWeek Healthcare Editor ...
Breaking Medicine Technology:CTI BioPharma Reports Third Quarter 2014 Financial Results 2CTI BioPharma Reports Third Quarter 2014 Financial Results 3CTI BioPharma Reports Third Quarter 2014 Financial Results 4CTI BioPharma Reports Third Quarter 2014 Financial Results 5CTI BioPharma Reports Third Quarter 2014 Financial Results 6CTI BioPharma Reports Third Quarter 2014 Financial Results 7CTI BioPharma Reports Third Quarter 2014 Financial Results 8CTI BioPharma Reports Third Quarter 2014 Financial Results 9CTI BioPharma Reports Third Quarter 2014 Financial Results 10CTI BioPharma Reports Third Quarter 2014 Financial Results 11CTI BioPharma Reports Third Quarter 2014 Financial Results 12Lilly Shares Insights from Decade-Long Technology Transfer Experience 2Lilly Shares Insights from Decade-Long Technology Transfer Experience 3Lilly Shares Insights from Decade-Long Technology Transfer Experience 4EHRs in the Age of Ebola: Discuss on InformationWeek 2EHRs in the Age of Ebola: Discuss on InformationWeek 3
... ROCKVILLE, Md., July 6 A procedure that sends targeted ... to treat a common type of irregular heartbeat, but little ... methods and circumstances for applying it, according to a new ... , , The report examines the use of a ...
... The Netherlands, July 6 Three new small and,medium ... - have joined public-private partnership TI Pharma by,participating in ... diseases, have a total budget of nearly 6 million ... formed by Syncom, Synvolux Therapeutics, and,University Medical Center Groningen, ...
Cached Medicine Technology:New AHRQ Study Finds Mixed Evidence on Use of Radiofrequency Catheter Ablation for Treating Atrial Fibrillation 2New AHRQ Study Finds Mixed Evidence on Use of Radiofrequency Catheter Ablation for Treating Atrial Fibrillation 3New Small and Medium Sized Enterprises Join TI Pharma by Signing Two New Projects 2
(Date:10/30/2014)... REV'D Provision Co. announced today that REV’D® ... unique service called, The Feed . The Feed ... athlete. The Feed has taken the nutritional knowledge used ... to pass that information on to the everyday athlete. ... on The Feed!” says REV’D® marketing manager Matt O’Connor. ...
(Date:10/30/2014)... The Woodlands, TX (PRWEB) October 30, 2014 ... hospital system, released today its 2014 third quarter ... hospitals across Texas boasted infection rates of only ... also reported patient satisfaction scores exceeding 98 percent. ... this past quarter, which included rising satisfaction scores,” ...
(Date:10/30/2014)... WEDNESDAY, Oct. 29, 2014 (HealthDay News) -- Scientists who ... the laboratory say their breakthrough could provide a new ... of stomach diseases. The team used human pluripotent ... cell in the body -- to grow the functional ... bacteria, a major cause of ulcers and stomach ...
(Date:10/30/2014)... WEDNESDAY, Oct. 29, 2014 (HealthDay News) -- Many ... near campus, even though tanning increases the risk ... popular among young adults, particularly white women, so ... students, health, the researchers said. "Public health ... student population awareness of the harms that indoor ...
(Date:10/30/2014)... News) -- A new vaccine that could help prevent ... by the U.S. Food and Drug Administration on Wednesday. ... ages of 10 and 25 from invasive meningococcal disease ... The bacteria can infect the bloodstream (sepsis) and ... It is a leading cause of bacterial meningitis, and ...
Breaking Medicine News(10 mins):Health News:Nutrition Experts at TheFeed.com Get REV'D 2Health News:Nutrition Experts at TheFeed.com Get REV'D 3Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 2Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 3Health News:Many U.S. Colleges Have Indoor Tanning Salons On, Near Campus: Study 2Health News:FDA Approves New Vaccine to Protect Against Meningitis 2
... In a survey of patients with chronic hepatitis C ... Digestive and Kidney Diseases-sponsored long-term treatment trial for patients ... approximately 40% acknowledged to interviewers at the time of ... the recent past used herbal products for health purposes. ...
... (TSX: MDS; NYSE:,MDZ), a leading provider of products ... filed restated 2007 quarterly reports under US GAAP,as ... 2007,annual report and financial statements in US GAAP ... restated quarterly reports also correct an error related ...
... APFC ) today announced that it will release ... 7, 2008. John R.,Gibson, Chairman and Chief Executive Officer, ... financial results and outlook of the,Company., The teleconference ... p.m.,PST. To access the call please dial (973) 582-2852 ...
... The Chrysler Foundation and,Kenosha (Wis.) Engine Plant today ... new Aquatics Center., Chrysler,s donation will help build ... the YMCA. The center will have two pools: a ... YMCA will break,ground for the aquatic center later this ...
... Iowa An anti-virus drug attacks influenza A by changing ... the virus to infect healthy cells, according to a recently ... Mei Hong, Iowa States John D. Corbett Professor in Chemistry, ... the effects of the antiviral drug amantadine on influenza A. ...
... research,organization, announced today that it has acquired the business ... located at Ninewells,Hospital and Medical School, Dundee, Scotland. Ninewells ... purchase of DDS supplements,Chiltern,s Clinical Research Unit in Slough ... has completed more than 700 Phase I trials.,The unit ...
Cached Medicine News:Health News:Silymarin does not affect virus activity or ALT levels in 2Health News:Silymarin does not affect virus activity or ALT levels in 3Health News:American Pacific to Release Financial Results and Hold Fiscal 2008 First Quarter Investor Teleconference 2Health News:The Chrysler Foundation and Kenosha Engine Plant Donate $100,000 to New YMCA Aquatics Center 2Health News:Iowa State chemists track how drug changes, blocks flu virus 2Health News:Chiltern Announced Today That it has Acquired the Business of Drug Development Solutions (DDS) 2Health News:Chiltern Announced Today That it has Acquired the Business of Drug Development Solutions (DDS) 3
... manual hemostasis analyzer that is ideal ... PTs, aPTTs, thrombins, fibrinogens and factor ... testing, this analyzer is small in ... time and labor saving benefits. Operation ...
... STart benchtop coagulation analyzers feature ... clot detection. This method eliminates ... other optically dense samples or ... and preprogrammed assays with curve ...
... Description,The STA-R Evolution is a fully-automated, ... the total laboratory automation line. Clotting, ... simultaneously in random access mode. The ... offers high throughput and rapid processing ...
The ACL 9000 together with an extensive test menu and superior technology is backed by high-quality service to keep the lab running efficiently....
Medicine Products: